Suppression of choroidal neovascularization by thioredoxin-1 via interaction with complement factor H

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 11, 2008, Pages 5118-5125

  Inomata, Yasuya ^a   Tanihara, Hidenobu ^a   Tanito, Masaki ^b   Okuyama, Hiroaki ^c   Hoshino, Yuma ^c   Kinumi, Tomoya ^d   Kawaji, Takahiro ^a   Kondo, Norihiko ^e   Yodoi, Junji ^e   Nakamura, Hajime ^c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^e KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A1; CD5 ANTIGEN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; CYSTEINE; FIBRINOGEN; LECTIN; SCAVENGER RECEPTOR; THIOREDOXIN 1; THIOREDOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG INHIBITION; EYE FUNDUS; IMMUNOHISTOCHEMISTRY; INJECTION; INTERVENTION STUDY; LASER COAGULATION; LEUKOCYTE; LIQUID; MALE; MASS SPECTROMETRY; MORBIDITY; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN ISOLATION; PROTEOMICS; RETINA MACULA AGE RELATED DEGENERATION; STAINING; SUBRETINAL NEOVASCULARIZATION; TRANSGENIC MOUSE; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY;

ANIMALS; BLOTTING, WESTERN; CHOROIDAL NEOVASCULARIZATION; COMPLEMENT FACTOR H; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; THIOREDOXINS;

EID: 56149108509     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.07-1659     Document Type: Article

References (30)

1. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents. Ophthalmology. 2004;111:1280-1287. (Pubitemid 38844822)
2. van Leeuwen R, Klaver CC, Vingerling JR, Hofman A, de Jong PT. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003;18:845-854.
3. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A. 1993;90:7915-7922. (Pubitemid 23260825)
4. Nozaki M, Raisler BJ, Sakurai E, et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A. 2006;103:2328-2333. (Pubitemid 43271669)
5. Bora PS, Sohn JH, Cruz JM, et al. Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J Immunol. 2005;174:491-497. (Pubitemid 40007439)
6. Edwards AO, Ritter R 3rd, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
7. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419-421. (Pubitemid 40530081)
8. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389. (Pubitemid 40530070)
9. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006;38:458-462.
10. Holmgren A. Thioredoxin. Annu Rev Biochem. 1985;54:237-271.
11. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol. 1997;15:351-369.
12. Saitoh M, Nishitoh H, Fujii M, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998;17:2596-2606. (Pubitemid 28221195)
13. Nishiyama A, Matsui M, Iwata S, et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J Biol Chem. 1999;274:21645-21650. (Pubitemid 129519705)
14. Nakamura H, Herzenberg LA, Bai J, et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci U S A. 2001;98:15143-15148. (Pubitemid 34013983)
15. Hoshino T, Nakamura H, Okamoto M, et al. Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med. 2003;168:1075-1083. (Pubitemid 37338936)
16. Liu W, Nakamura H, Shioji K, et al. Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation. 2004;110:1276-1283. (Pubitemid 39202345)
17. Takagi Y, Mitsui A, Nishiyama A, et al. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci U S A. 1999;96:4131-4136. (Pubitemid 29169048)
18. Bora NS, Kaliappan S, Jha P, et al. Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H. J Immunol. 2006;177:1872-1878. (Pubitemid 44092526)
19. Hirota K, Matsui M, Iwata S, et al. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci U S A. 1997;94:3633-3638. (Pubitemid 27180424)
20. Kinumi T, Ogawa Y, Kimata J, et al. Proteomic characterization of oxidative dysfunction in human umbilical vein endothelial cells (HUVEC) induced by exposure to oxidized LDL. Free Radic Res. 2005;39:1335-1344. (Pubitemid 43023798)
21. McRae JL, Duthy TG, Griggs KM, et al. Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein. J Immunol. 2005;174:6250-6256.
22. Motohashi K, Kondoh A, Stumpp MT, Hisabori T. Comprehensive survey of proteins targeted by chloroplast thioredoxin. Proc Natl Acad Sci U S A. 2001;98:11224-11229. (Pubitemid 32928710)
23. Walport MJ. Complement: first of two parts. N Engl J Med. 2001;344:1058-1066.
24. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol. 2004;41:355-367. (Pubitemid 38639887)
25. Kirkitadze MD, Barlow PN. Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev. 2001;180:146-161.
26. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem. 2001;276:12292-12300. (Pubitemid 37385399)
27. Hansson HA, Holmgren A, Norstedt G, Rozell B. Changes in the distribution of insulin-like growth factor I, thioredoxin, thioredoxin reductase and ribonucleotide reductase during the development of the retina. Exp Eye Res. 1989;48:411-420. (Pubitemid 19076152)
28. Tanito M, Masutani H, Kim YC, et al. Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Invest Ophthalmol Vis Sci. 2005;46:979-987. (Pubitemid 41321036)
29. Tanito M, Masutani H, Nakamura H, et al. Attenuation of retinal photooxidative damage in thioredoxin transgenic mice. Neurosci Lett. 2002;326:142-146. (Pubitemid 34607579)
30. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12:682-687. (Pubitemid 43865238)